

pared to adalimumab and infliximab when using actual drug utilization data from US commercially-insured population.

PMS16

POTENTIAL COST SAVING OF EPOETIN ALFA COMPARED TO AUTOLOGOUS BLOOD DONATION OR TO NO-BLOOD-CONSERVATION-STRATEGY BEFORE ELECTIVE HIP OR KNEE SURGERY DUE TO REDUCTION IN ALLOGENEIC BLOOD TRANSFUSIONS AND ITS SIDE EFFECTS

Tomeczkowski J¹, Frietsch T², Müller A³, Schleppeers A⁴, von Heymann C⁵

¹Janssen-Cilag GmbH, Neuss, Germany, ²Ostseelklinik Damp GmbH, Damp, Germany, ³Alfred Müller, München, Germany, ⁴Berufsverband Deutscher Anästhesisten, Nürnberg, Germany, ⁵Virchow-Klinikum/Campus Charité Mitte, Berlin, Germany

OBJECTIVES: Transfusion of allogeneic blood still is common in orthopedic surgery albeit associated with higher morbidity and mortality. This analysis evaluates from the perspective of a German hospital the potential cost savings of Epoetin alfa compared to predonated autologous blood transfusions or to no-blood-conservation-strategy during elective hip and knee replacement surgery by reducing allogeneic blood transfusions and their associated infectious adverse events. **METHODS:** Individual patients (n = 10,000) were created based on data from controlled trials, the German DRG institute (InEK) and various publications and entered into a stochastic model (Monte-Carlo) one of three treatment arms: Epoetin alfa, preoperative autologous donation and no-blood-conservation-strategy. The model is focused on the costs and events of the procedure and follow-up. The model was validated by an independent external consultant. Clinical and economical variables were obtained from clinical trial databases, the German DRG System, patient records and medical publications - in particular cost per transfusion (allogeneic red blood cells: € 320/unit and autologous red blood cells: € 280/unit), pneumonia treatment (€ 5,000), and length of stay (€ 300/day). Probabilistic sensitivity analyses were performed to determine which, if any, factors had an influence on the model's clinical and cost outcomes. **RESULTS:** At acquisition costs of € 375/40,000 IE Epoetin alfa is cost saving compared to autologous blood donation, and at € 185/40,000 IE compared to no-blood-conservation-strategy. The results were most sensitive to the cost of Epoetin alfa, blood units and hospital days. **CONCLUSIONS:** Upcoming shortages and increasing prices of red blood cells will make Epoetin alfa an attractive blood conservation strategy for anemic patients at reasonable costs, due the reduction in allogeneic blood transfusions and their associated infectious adverse events.

PMS17

THE EFFECT OF BIOLOGICAL TREATMENT ON WORK PRODUCTIVITY AND PRODUCTIVITY COSTS OF RHEUMATOID ARTHRITIS PATIENTS

Klimes J¹, Dolezal T², Vocelka M³, Petrikova A⁴, Kruntoradova K⁵

¹Charles University, Faculty of Pharmacy, Hradec Kralove, Czech Republic, ²Institute for Health Economics and Technology Assessment, Prague, Czech Republic, ³Third Faculty of Medicine, Charles University in Prague, Praha 10, Czech Republic, ⁴VFU Brno, Brno, Czech Republic, ⁵Czech Technical University in Prague, Faculty of Biomedical Engineering, Kladno, Czech Republic

OBJECTIVES: Biologics represent significant costs of rheumatic diseases treatment. Our study has focused on productivity comparison of rheumatoid arthritis (RA) patients treated with biologics and patients on DMARDs who are indicated to biologic treatment however therapy is unavailable due to economic limitations. **METHODS:** Work Productivity and Activity Impairment Questionnaire (WPAI:RA) was administered to two groups of patients - patients treated with biologics (n=76) with low disease activity and patients just on DMARDs (n=23) with high disease activity (DAS28 score \geq 5.1). All patients were in productive age. Patients' demographics, clinical and PRO parameters (DAS28, HAQ, time from diagnosis) and working statuses we collected by rheumatologist. Productivity costs were calculated by friction cost approach using friction period of 130 work-days and average monthly gross income as denominator. **RESULTS:** Mean patients' age on biologics and on DMARDs were 41.0 years (21-61) and 45.7 (22 - 61), respectively. Mean time from diagnosis of biologics and DMARDs groups were 13.5 and 11.6 years, respectively. Average HAQ and DAS28 were 0.77 and 2.64, respectively for patients on biologics and 1.14, 5.62, respectively for patients on DMARDs. Patients on biologics were slightly more work-disabled (26.3%) compare to 25.0% DMARDs patients. Overall work-impairment (for patients that reported any work-impairment) for patients on biologics and for patients on DMARDs was 28.1% and 49.6%, respectively. Patients on biologics reported less reduction of daily activities (39.8%) in compare to patients on DMARDs (50.5%). Average annual productivity costs per one patient on biologics and for DMARDs patient were € 1802 and € 2769, respectively. **CONCLUSIONS:** Despite of the fact, patients on biologics had longer time from diagnoses, they reported significantly lower work-impairment and reduction of daily activities in compare to DMARDs patients, which reflected about 53.6% higher productivity costs for patients on DMARDs. Biologic treatment preserves productivity and save productivity costs.

PMS18

BURDEN OF RHEUMATOID ARTHRITIS IN THE CZECH REPUBLIC - DIRECT AND PRODUCTIVITY COSTS

Klimes J¹, Vocelka M², Dolezal T³, Petrikova A⁴

¹Charles University, Faculty of Pharmacy, Hradec Kralove, Czech Republic, ²Third Faculty of Medicine, Charles University in Prague, Praha 10, Czech Republic, ³Institute for Health Economics and Technology Assessment, Prague, Czech Republic, ⁴VFU Brno, Brno, Czech Republic

OBJECTIVES: International pharmaco-economic studies suggest Health Assessment Questionnaire (HAQ) as an important predictor of evaluation both direct and productivity costs. Costs are supposed to increase with increasing HAQ score. Therefore, we calculated direct and productivity costs for five groups of patients according to their HAQ (<0.6, 0.6-1.1, 1.1-1.6, 1.6-2.1, \geq 2.1) to confirm this assumption also in the Czech Republic. **METHODS:** This calculation was based on a retro-

spective cross-sectional study. We included 126 patients with rheumatoid arthritis, aged 18-84 years either at working status, part-time disabled or full-time disabled. For estimation of direct medical costs, we used microcosting method retrospectively reviewing individual patients' medical records. For calculation of productivity costs we excluded patients older than 63 years of age (retirement pensioners). We used friction costs approach (FCA) with defined friction period of 130 workdays, based on patients' absenteeism. Productivity of part-time-disabled and full-time disabled patients were assumed to be deteriorated by 52% and 70%, respectively, based on the Czech law on pension insurance. The height of average monthly income in year 2010, €960.3 was used as denominator. Costs were expressed as mean value per one patient with RA in each of the HAQ-group. **RESULTS:** Average patients' age was 57.3 years; average time from diagnosis was 17.5 years with mean HAQ score 1.4 and mean DAS28 3.62. Mean annual medical direct costs, for each HAQ-group, were €4076.7, €5950.2, €4691.3, €6932.1, and €6727.1, respectively. Mean annual indirect costs associated with productivity loss were €481.5, €1178.6, €1267.7, €1585.6, and €2122.5, respectively. **CONCLUSIONS:** Direct and productivity costs for patients with rheumatoid arthritis are closely related to the height of HAQ score. Total (direct and productivity) annual mean costs were €7135.6. 31.0% of all patients were treated with biological treatment which represented up to 79.4% of the overall direct medical costs.

PMS19

THE ECONOMIC BURDEN OF POST-MENOPAUSAL OSTEOPOROSIS AND RELATED FRACTURES IN GREECE

Athanasakis K¹, Karampli E¹, Hollandezos M¹, Papagiannopoulou V², Badamgarav E³, Intorcica M⁴, Kyriopoulos J¹

¹National School of Public Health, Athens, Greece, ²AMGEN Hellas, Marousi, Greece, ³Amgen, Thousand Oaks, CA, USA, ⁴Amgen S.A., Barcelona, Spain

OBJECTIVES: To determine the healthcare resource use (HRU) and costs attributable to osteoporosis and osteoporosis-related fractures in post-menopausal women in Greece. **METHODS:** A multi-point data collection procedure, based on strictly-structured interviews with 137 geographically distributed physicians, was used to construct and populate the disease management model for women with post-menopausal osteoporosis (PMO) aged >50years. The model was further validated by a group of 12 experts. Secondly, all HRU items in the model were costed in order to provide per-patient costs of treatment. Cost variables included costs of consultations, laboratory tests, osteoporotic medication, dietary supplements, hospitalization due to fractures and rehabilitation, allcalculated from a third-party payer perspective (Euros, 2011) for a 1year timeframe (retrospective). **RESULTS:** The mean annual cost per PMO patient was €1,384.67 (95%CI: 423.27 - 7281.16). When distinguishing between women with established (PMO with a previous fracture) (27.6% of total) and non-established PMO, the mean annual cost per patient was €2027.46 (95%CI: 508.09-7241.90) and €1139.63 (95%CI: 461.86 - 1324.44) respectively. For PMO women with an established osteoporosis for <1year the mean annual cost was significantly higher compared to those with an established osteoporosis for >1year €2714.98 (95%CI: 820.17 - 7284.42) versus €1805.54 (95%CI: 508.09 - 7241.77). The mean annual cost per patient with a fracture was €4,334.27 (95%CI: 1,452.86 - 10,730.17) for a hip, €2,723.27 (95%CI: 1,470.39 - 7,839.55) for a vertebral and €1,731.35 (95%CI: 1,131.17 - 1,942.48) for a Colles fracture respectively. The sensitivity analysis (\pm 10% change of baseline values) showed that the factors with the greatest impact on total cost were the probability of established osteoporosis, the probability of a fracture in the previous 12 months, cost of parathormone treatment and the cost of patient monitoring. **CONCLUSIONS:** Treatment of osteoporosis is costly. Efforts to control the main osteoporosis cost drivers and hence its economic impact on the health care budgets, are necessary.

PMS20

TREATMENT OF PATIENTS WITH MODERATE AND SEVERE PSORIASIS - COST-OF-ILLNESS IN THE CZECH REPUBLIC

Petrikova A¹, Klimes J², Dolezal T³, Marinov L⁴, Petrova G⁵

¹VFU Brno, Brno, Czech Republic, ²Charles University, Faculty of Pharmacy, Hradec Kralove, Czech Republic, ³Institute for Health Economics and Technology Assessment, Prague, Czech Republic, ⁴Medical University, Sofia, Bulgaria, ⁵Medical University, Faculty of Pharmacy, Sofia, Bulgaria

OBJECTIVES: Psoriasis (prevalence 2-3%) is not directly life-threatening disease. However, patients suffering from psoriasis and psoriatic arthritis (PsA) are experiencing lower quality of life. Treatment of these diseases represents a significant financial burden for the healthcare system. **METHODS:** Study was based on 12-months retrospective electronic questionnaire reported by dermatologist. We used societal perspective using friction cost approach method for productivity costs calculation. Patients' demographics, clinical data (PASI and BSA index), direct costs (inpatient/outpatient care, local/systemic treatment etc.), productivity costs (invalidity, sick leave) and on QoL (EQ-5D, DLQI) were collected. **RESULTS:** A total of 256 patients participated in the study, average patients' age was 46.79 years (9-75 years), average time from diagnosis was 25.52 years with average PASI 13.76, BSA 28.09%, DLQI 11.74 and EQ-5D 0.7633. Occurrence of PsA was 34.4%. Major direct costs driver was phototherapy (47% of direct costs), systematic treatment (17%) and inpatient care (15%). Within the productive-age patients (18-63 years), 8.6% of patients were fully disabled, 7.4% partially disabled, 73% patients were work-active, and 11% were unemployed, retired or students. 17.2% of work-active patients reported incapacity to work with average duration of 33 days in previous 6 months. Mean indirect costs associated with productivity loss were €848.3 per work-active patient per year €1343.0 per work-active patient with PsA. Mean annual costs per patient with moderate to severe psoriasis and/or PsA were calculated to €3736.5 (direct costs 77%, €2888.2). Mean annual costs per patient with PsA were €4328.3 including €2985.3 for direct costs (69%). **CONCLUSIONS:** Direct costs remain major

drivers of cost consumption in the treatment of patients with psoriasis and PsA in the Czech Republic. Cohort in our study was not treated with biological treatment which would certainly increase the costs therefore further study is required to access the cost-effectiveness of such treatment in the Czech Republic.

PMS21

DIFFERENCES IN COST-OF-ILLNESS AND QUALITY OF LIFE BETWEEN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS IN SOUTH KOREA

Lee TJ¹, Park BH¹, Son HK¹, Kim JW², Shin K³, Lee EB², Song YW²

¹Seoul National University, Seoul, South Korea, ²Seoul National University Hospital, Seoul, South Korea, ³Seoul National University Hospital, Seoul, South Korea

OBJECTIVES: To estimate and compare cost-of-illness (COI) and health-related quality of life (HRQOL) of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in South Korea. **METHODS:** Patients with RA (n=196) and AS (n=191) were surveyed by face-to-face interviews at the Rheumatology Clinic of Seoul National University Hospital. Direct costs [medical costs (treatment, drug, private physiotherapy, traditional Chinese medicine, other alternative medicine), non-medical costs (travel, dietary supplements, auxiliary device, home assistance)], indirect costs (productivity loss due to job loss and sick leave) and deterioration in HRQOL of RA and AS patients were measured. HRQOL was assessed using KEQ-5D. Factors associated with COI and HRQOL were analyzed using multiple regression and multivariate logistic regression. **RESULTS:** COI of AS patients was more than double compared to that of RA patients (RA: 6,446,376 Korean Won, AS: 12,433,629 Korean Won) but HRQOL of RA patients was lower than that of AS patients (RA: 0.49, AS: 0.62). As functional severity worsened in both diseases, the total costs increased accordingly (RA: functional class (FC) I: 4,230,204 Korean Won, FC II: 7,250,674 Korean Won, FC III: 8,046,434 Korean Won, FC IV: 8,206,215 Korean Won, AS: FC I: 8,125,096 Korean Won, FC II: 13,995,292 Korean Won, FC III, IV: 30,118,247 Korean Won) and the HRQOL scores decreased (RA: FC I: 0.67, FC II: 0.50, FC III: 0.29, FC IV: 0.23, AS: FC I: 0.72, FC II: 0.61, FC III, IV: 0.24). Functional severity was the major determinant of COI and HRQOL in RA and AS. **CONCLUSIONS:** Although the HRQOL of AS patients was not as low as that of RA patients, the COI of AS patients was higher than that of RA patients. Considering the relatively low HRQOL and relatively low medical costs of RA patients, re-examination of reimbursement plan of Korean National Health Insurance is needed to figure out this problem.

PMS22

THE BURDEN OF ILLNESS OF OSTEOPOROSIS IN CANADA

Tarride JE¹, Hopkins R¹, Leslie WD², Morin S³, Adachi J¹, Papaioannou A¹, Bessette L⁴, Brown JP⁵, Goeree R¹

¹McMaster University, Hamilton, ON, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³McGill University, Montreal, QC, Canada, ⁴CHUL, Quebec, QC, Canada, ⁵Laval University, Quebec, QC, Canada

OBJECTIVES: Since the 1993 estimate of the burden of osteoporosis in Canada, the population has aged and new treatment options have been introduced. The study purpose was to estimate the current burden of illness due to osteoporosis in Canadians aged 50 and over. **METHODS:** Analyses were conducted using five national administrative databases from the Canadian Institute for Health Information for the fiscal-year ending March 31 2008 (FY 2007/08). Gaps in national data were supplemented by provincial data extrapolated to national levels. Osteoporosis-related fractures of the hip, humerus, vertebra, wrist, other sites and multiple sites were identified using a combination of most responsible diagnosis and intervention codes. Fractures associated with severe trauma codes were excluded from the analysis. Costs, expressed in 2010 dollars, were calculated for osteoporosis-related hospitalizations, emergency care, same day surgeries, rehabilitation, continuing care, home care, long-term care, prescription drugs, physician visits and productivity losses. Sensitivity analyses were conducted to measure the impact on the results of key assumptions. **RESULTS:** Osteoporosis-related fractures were responsible for 57,413 acute care admissions and 832,594 hospitalized days in FY 2007/08. Acute care costs were estimated at \$1.2 billion. When outpatient care, prescription drugs and indirect costs were added, the overall yearly cost of osteoporosis was over \$2.3 billion for the base case analysis and as much as \$3.9 billion if a proportion of Canadians were assumed to be living in long-term care facilities due to osteoporosis. **CONCLUSIONS:** Osteoporosis is a chronic disease that results in a substantial economic burden to the Canadian society.

PMS23

ANALYSIS OF INDIRECT COSTS FOR CARE OF RHEUMATOID ARTHRITIS PATIENTS USING LARGE COHORT DATABASE, IORRA, IN JAPAN

Igarashi A¹, Hoshi D², Tanaka E², Inoue E², Nakajima A², Momohara S², Taniguchi A², Yamanaka H², Tsutani K¹

¹Tokyo Univ. Faculty of Pharmacy, Tokyo, Japan, ²Tokyo Women's Medical University, Tokyo, Japan

OBJECTIVES: To examine annual indirect cost in large-scale rheumatoid arthritis (RA) patient cohort (IORRA) in Japan. **METHODS:** From patients' perspective, we calculated indirect costs of RA patients, participants of the 15-17th IORRA studies in Oct. 2007- Oct. 2008. Productivity losses due to occasional absence from working and those due to permanent retirement were separately estimated, by multiplying average time with average wage, stratified by age & sex distribution of the cohort. We also assessed correlations between these costs and RA disease activity, disability level and QOL. **RESULTS:** Data from 5284 RA patients were extracted. A total of 34.8% of those were staying working in spite of RA. However, 9.9% reduced their working time and 8.4% quit their job due to RA. In average, RA patient missed 435.1 working hours per 1 year. By multiplying average wage, JPY1,753, annual indirect costs per RA patient was estimated to JPY762,000. For whole RA patients in Japan (n=700,000), it would be JPY53.3 billion per year. These costs increased progressively with worsening RA disease activity, disability level, or QOL. For example,

patients with lower EQ-5D score (less than 0.5) missed more working time than those with higher one did (more than 0.8). Average missed time for working and annual indirect cost among them were 1,087 hours versus 275.8 hours and JPY1,906,000 versus JPY484,000, respectively. With same cohort data, we had already proved that direct costs also had same trend. Total costs for RA patient were JPY4,800,000 (JPY2.9mil. for direct cost and JPY1.9mil. for indirect cost) for patients with lower EQ-5D score and JPY1,800,000 (JPY1.3mil. for direct cost and JPY0.5mil. for indirect cost) for patients with higher one from societal perspective. **CONCLUSIONS:** Heavy economic burden lies in RA patients and grows heavier as the disease state is exacerbated using IORRA database. The increase indirect cost may be suppressed by proactively controlling RA.

PMS24

THE COST OF CARE OF RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS PATIENTS IN TERTIARY CARE RHEUMATOLOGY UNITS IN TURKEY

Malhan S¹, Pay S², Ataman S³, Dalkilic E⁴, Dinc A², Erken E⁵, Ertenli F⁶, Ertugrul E⁷, Gogus F⁸, Hamuryudan V⁹, Inanc M¹⁰, Karaaslan Y¹¹, Karadag O¹², Karakoc Y¹³, Keskin C¹⁴, Kısacık B¹⁵, Kiraz S⁶, Okselel F¹⁶, Okşuz E¹⁷, Parıldar T¹⁸, Sari I¹⁹, Soy M²⁰, Senturk T²¹, Taylan A²²

¹Baskent University Faculty of Health Sciences, Ankara, Turkey, ²Gulhane Military Medical Academy, Ankara, Turkey, ³Ankara University Faculty of Medicine, Ankara, Turkey, ⁴Uludağ University Faculty of Medicine, Bursa, Turkey, ⁵Cukurova University Faculty of Medicine, Adana, Turkey, ⁶Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁷Kayseri Erciyes University Faculty of Medicine, Kayseri, Turkey, ⁸Gazi University Faculty of Medicine, Ankara, Turkey, ⁹Istanbul University Cerrahpaşa Faculty of Medicine, Istanbul, Turkey, ¹⁰Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ¹¹Ankara Numune Training and Research Hospital, Ankara, Turkey, ¹²Diyarbakir Training and Research Hospital, Diyarbakir, Turkey, ¹³Bursa Sevgi Yilmaz Training and Research Hospital, Bursa, Turkey, ¹⁴Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey, ¹⁵Gaziantep University Faculty of Medicine, Gaziantep, Turkey, ¹⁶Ege University Faculty of Medicine, Izmir, Turkey, ¹⁷Baskent University Faculty of Medicine, Ankara, Turkey, ¹⁸Celal Bayar University Faculty of Medicine, Manisa, Turkey, ¹⁹Izmir Bozyaka Training and Research Hospital, Izmir, Turkey, ²⁰Bolu Izzet Baysal University Faculty of Medicine, Bolu, Turkey, ²¹Adnan Menderes University Faculty of Medicine, Aydın, Turkey, ²²Izmir Tepecik Training and Research Hospital, Izmir, Turkey

OBJECTIVES: To determine direct and indirect cost due to rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in Turkey. **METHODS:** An expert panel composed of 21 experts chosen from all national tertiary care rheumatology units (n=53) was convened to estimate the direct and indirect costs of care of patients with RA and AS in Turkey, using "cost-of-illness" methodology. To measure indirect costs, the number of days of sick leave, the extent of disability, and the levels of early retirement and early death were also evaluated. Lost productivity costs were calculated using the "human capital approach", based on the minimum wage. **RESULTS:** The total annual direct costs were 2.917,03 Euro per RA patient and 3.565,9 Euro for each AS patient. The direct costs were thus substantial, but the indirect costs were much higher because of extensive morbidity and mortality rates. The total annual indirect costs were 7.058,99 Euro per RA patient and 6.989,81 for each AS patient. Thus, the total cost for each RA patient was 9.976,01 Euro and that for an AS patient 10.555,72 Euro, in Turkey. **CONCLUSIONS:** From the perspective of those who pay for health care, both RA and AS has become a burden in Turkey. The cost of lost productivity is higher than the medical cost. Another important conclusion is that indirect costs constitute 70% and 66% of total costs in patients with RA and AS, respectively. The annual cost of RA for whole Turkish population is 2.130.424.680 Euro. This amount contributes to 0.37% of the GDP in Turkey. Whereas for AS, the annual cost of disease in Turkey is 2.209.201.904 Euro and this corresponds to 0.38% of the GDP. To conclude, RA and AS diseases have total burden of 4.339.626.584 Euro that is 0.75% of the Turkish GDP.

PMS25

EVALUATION OF DIRECT COSTS FOR THE TREATMENT OF ACTIVE JUVENILE RHEUMATOID ARTHRITIS USING BIOLOGICS

Yagudina R, Kulikov A, Zinchuk I

First MGPU named after I.M. Sechenov, Moscow, Russia

OBJECTIVES: Evaluate direct costs for the treatment of patient with active juvenile rheumatoid arthritis (JRA) in the inefficiency of conventional therapy. **METHODS:** Direct costs applied to patient, health care and society in process of medical care provision were evaluated. In the study direct costs included cost of biologics for the treatment of active JRA, therapy cost of the most common side effects caused by biologics use, cost of inpatient care and cost of out-patient diagnostic and treatment of JRA patients. **RESULTS:** Therapy cost with Etanercept and Abatacept was evaluated on the first stage including spending on one patient treatment with active JRA with body weight 15 till 65 kg. during one year after three months of inefficient conventional therapy. Biologics doses and dosing regimen were defined on the basis of application sheet. Calculated annual therapy cost for Etanercept varied from 11,752 EUR to 23,503 EUR depending on body weight and for Abatacept from 8,879 EUR to 26,638 EUR respectively. During cost analysis authors considered only very often (>1/10) and often (>1/10, < 1/10) occurred side effects. Thus, cost of side effects treatment caused by Etanercept use resulted in 44 EUR and for Abatacept – 69 EUR. Next stage of cost analysis was evaluation of therapy cost for patients with JRA according standard of inpatient treatment è standard of out-patient treatment. Cost of 30 days of inpatient care and 14 months of out-patient care was considered during cost analysis for the treatment of patients with JRA. Cost of inpatient and out-patient care for patient with JRA excluding biologics cost amounted to 33585 EUR. **CONCLUSIONS:** Finally total direct costs for the treatment of patient with JRA during one year with body weight from 15 till 65 kilogram varied from 45,380 EUR to 57,132 EUR for Etanercept and from 42,534 EUR to 60,292 EUR for Abatacept respectively.